Accelerating Development of Vaccines for Cancer

The Cancer Vaccine Consortium is establishing solutions to common challenges in cancer vaccine use, development, and commercialization.

The Consortium's membership of industrial and academic leaders across the United States and Europe complements the CRI/LICR Cancer Vaccine Collaborative's international network of academic clinical and laboratory centers. Working in parallel under the Cancer Research Institute, the two programs encompass all points along the cancer vaccine and immunotherapy development spectrum, from laboratory and clinical discovery, reagent production, and immune response monitoring, to therapeutic product development and approval.